Despite the advances in treating HER2-positive breast cancer, many questions remain unanswered, such as how to impact prior resistance or affect a sanctuary site, and the optimal use of these novel compounds with regard to disease setting, treatment sequence, and combination regimens (233). The gene discussed is ERBB2; the disease is breast carcinoma.